Continuing medical educationHair disorders in patients with cancer
Section snippets
Epidemiology
Key point Hair changes attributed to anticancer therapies are expected to occur in ≥65% of patients receiving cytotoxic therapies, 15% with targeted therapies, <2% on immunotherapies, and up to 100% in areas treated with radiotherapy
The widespread use of systemic anticancer therapies, their numerous combinations, and underreporting of hair disorders yield mixed incidence reports (Table I), but these events in varying degrees of severity are frequent across almost all types of interventions. The estimated
Clinical features
Key point The spectrum of hair disorders in cancer patients encompasses all hair changes, including alopecia, pigmentary changes, textural changes, and cycle alterations
Hair disorders in cancer patients occur because of disturbances in hair follicle cycling and functioning and hair shaft synthesis, which results in effluvium during anagen or catagen.3, 4, 75 Clinical features of hair disorders induced by anticancer therapies vary depending on the anticancer therapy given, its half-life, dose, schedule,
Etiology and pathogenic mechanisms
Key points The pathogenic mechanisms of anticancer therapy–induced alopecia and other hair disorders varies depending on causal therapy The hair matrix keratinocytes of anagen hair follicles have a high mitotic activity, which makes them especially vulnerable to anticancer therapies Paradoxically, some anticancer therapies can promote hair growth and textural and hair color changes
Although the clinical manifestation of CIA from different therapies may be similar (albeit with subtle variations), accumulating
Hair disorder severity grading
Key point Adverse events in oncology clinical trials are graded using the Common Terminology Criteria for Adverse Events
The documentation of AEs is critical for patient safety and for the development of a toxicity profile for each anticancer drug/regimen. In the oncology literature, alopecia is graded by the following AE grading instruments; the World Health Organization,126 Dean scale,127 the Eastern Cooperative Oncology Group,128 Sredni et al,129 the National Cancer Institute,130 the EGFR Inhibitors
Quality of life in patients with cancer with hair disorders
Key points Chemotherapy-induced scalp, eyelash, and eyebrow alopecia lead to a negative psychosocial impact The impact of other hair disorders in oncology has not been reported, but is likely significant
Hair-related AEs have a profound impact on cancer patient QoL. CIA is one of the most clinically visible and distressing AEs,2 and has been cited as the most disturbing anticipated AE by 58% of breast cancer patients before chemotherapy.134 In a multicenter study, 55% of 168 breast cancer patients reported
Management
Key point Most preventive or reactive strategies are based on uncontrolled studies; however, the US Food and Drug Administration has cleared 2 dynamic scalp cooling devices for the prevention of CIA in patients treated with cytotoxic chemotherapies for solid tumors
Challenges and future perspectives
Despite the prevalence and psychosocial impact of anticancer therapy–induced hair disorders, research into their clinical presentation, pathophysiology, and management strategies has not received the attention it justifies. A comprehensive knowledge of the impact of hair disorders on QoL would be critical to optimize the shared decision-making process between doctors and patients regarding cancer therapies. As patients live longer on cancer therapies, there is a need to identify risk factors of
References (172)
- et al.
Chemotherapy-induced alopecia
J Am Acad Dermatol
(2012) - et al.
Alopecia in patients treated with molecularly targeted anticancer therapies
Ann Oncol
(2015) - et al.
Cyclophosphamide in the treatment of common neoplastic diseases of childhood
J Pediatr
(1962) - et al.
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group
Eur J Cancer
(1999) - et al.
A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma
Clin Oncol (R Coll Radiol)
(1993) - et al.
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group
Eur J Cancer
(1997) - et al.
CPT-11 (irinotecan) in the treatment of colorectal cancer
Eur J Cancer
(1995) - et al.
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
GERCOR Eur J Cancer
(1999) - et al.
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
Ann Oncol
(2009) - et al.
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
Gynecol Oncol
(2004)
Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features
Clin Oncol (R Coll Radiol)
Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial
Eur J Cancer
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Eur J Cancer
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients
J Am Acad Dermatol
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
Ann Oncol
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia
Hematol Oncol Stem Cell Ther
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
Ann Oncol
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib
J Am Acad Dermatol
Trichomegaly of the eyelashes following treatment with cetuximab
Ann Oncol
Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia
Blood
Pathobiology of chemotherapy-induced hair loss
Lancet Oncol
Radiation-induced temporary alopecia after embolization of cerebral arteriovenous malformations
Clin Neurol Neurosurg
Dermatoscopy of hair shaft disorders
J Am Acad Dermatol
RASopathic alopecia: hair changes associated with vemurafenib therapy
J Am Acad Dermatol
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet
Cancer statistics, 2016
CA Cancer J Clin
Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review
Psychooncology
Chemotherapy-induced alopecia management: clinical experience and practical advice
J Cosmet Dermatol
Radiation-induced alopecia
Int J Trichology
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
Br J Dermatol
Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood
Bone Marrow Transplant
Alopecia with endocrine therapies in patients with cancer
Oncologist
Drug-induced hair loss and hair growth
Drug Saf
Changes in self-concept and body image during alopecia induced cancer chemotherapy
Support Care Cancer
Unanticipated toxicities from anticancer therapies: survivors' perspectives
Support Care Cancer
Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study
J Clin Oncol
Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study
Support Care Cancer
Effect of large intermittent intravenous doses of cyclophosphamide in lymphoma
Cancer
Clinical evaluation of a new alkylating agent: cytoxan (cyclophosphamide)
Cancer
Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer
Breast Cancer Res Treat
Cyclophosphamide in the management of advanced bronchial carcinoma
Thorax
A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia
Cancer Res
Daunorubicin in the therapy of acute granulocytic leukemia
Cancer Res
Taxotere [package insert]
Docetaxel
J Clin Oncol
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
Br J Cancer
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
J Clin Oncol
Permanent alopecia in women being treated for breast cancer
Clin J Oncol Nurs
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer
J Clin Oncol
Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer
Invest New Drugs
Cited by (55)
Melatonin Protects K15<sup>+</sup> Human Hair Follicle Stem Cells and Hair Matrix Keratinocytes against Paclitaxel-Induced Damage Ex Vivo
2024, Journal of Investigative DermatologyKeratin 17 Impacts Global Gene Expression and Controls G2/M Cell Cycle Transition in Ionizing Radiation–Induced Skin Damage
2023, Journal of Investigative DermatologyLow-Intensity Ultrasound as a Potential Intervention Strategy to Protect Human Scalp Hair Follicles from Taxane-Induced Toxicity
2023, Journal of Investigative DermatologyMedication-induced hair loss: An update
2023, Journal of the American Academy of DermatologyEGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects
2023, Anais Brasileiros de Dermatologia
Supported in part by National Institutes of Health/National Cancer Institute Cancer Center support grant P30 CA008748. Dr Lacouture is supported by the RJR Oncodermatology Fund. Dr Freites-Martinez is partially supported by Beca Excelencia, Academia Española de Dermatología y Venereología–Fundación Piel Sana. Dr Paus is supported by the National Institute of Health Research Manchester Biomedical Research Centre.
Dr Shapiro has been a consultant for Aclaris, Samumed, Incyte, Replicel Life Sciences, and Shook, Hardy, and Bacon LLP, who represent Sanofi Aventis US LLC. Dr Goldfarb has a speaking, consultant, or advisory role with Adgero Biopharmaceuticals, AMAG Pharmaceuticals, Procter and Gamble, and Valeant women's health pharmaceuticals. Dr Nangia received clinical trial funding from Paxman to the Baylor College of Medicine for conduct of the SCALP trial. Dr Paus has a consultant role with or receives research funding from Giuliani/Italy and Unilever/UK, and is founder/owner of Monasterium Laboratory/Germany. Dr Lacouture has a speaking, consultant, or advisory role with Abbvie, Quintiles, Boehringer Ingelheim, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foamix, Adgero Bio Pharmaceuticals, Janssen R&D, Novartis, Paxman, and Novocure, and also receives research grants from Berg and Bristol-Myers Squibb. Drs Freites-Martinez and Jimenez have no conflicts of interest to disclose.
Date of release: May 2019
Expiration date: May 2022